Upper-extremity Spasticity-reducing Treatment in Adjunct to Movement Training and Orthoses in Children with Cerebral Palsy at Gross Motor Function- and Manual Ability Classification System Levels IV-V: A Descriptive Study

Dev Neurorehabil. 2020 Aug;23(6):349-358. doi: 10.1080/17518423.2019.1655677. Epub 2019 Aug 22.

Abstract

Covering a 20-year period of work with children with severe cerebral palsy (CP) within a Swedish habilitation service, changes in passive wrist extension with fingers extended (PWE-FE) and current hand function are described and compared between children receiving systematic upper-extremity treatment with botulinum neurotoxin type A and intervention programs from before 7 years of age (Group 1, n = 7), those whom for various reasons did not undergo this treatment (Group 2, n = 10), and those not having the option to receive treatment until later during childhood/adolescence (Group 3, n = 8). Group 3 showed more critical and less normal PWE-FE values for both wrists, and poorer hand function scores, particularly compared with Group 1. Findings cautiously suggest that repeated upper-extremity spasticity-reducing treatment and movement training/orthoses from an early age may help prevent critical loss of passive range of motion of the wrist joint flexion/extension and promote hand function development in children with severe CP.

Keywords: Severe cerebral palsy; botulinum toxin; development; hand function; passive wrist extension; upper-extremity interventions.

MeSH terms

  • Botulinum Toxins, Type A / administration & dosage
  • Botulinum Toxins, Type A / therapeutic use*
  • Cerebral Palsy / pathology
  • Cerebral Palsy / rehabilitation
  • Cerebral Palsy / therapy*
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Exercise Therapy / methods*
  • Female
  • Hand / physiopathology
  • Humans
  • Injections, Intramuscular
  • Male
  • Movement
  • Muscle Spasticity
  • Neurological Rehabilitation / methods
  • Neuromuscular Agents / administration & dosage
  • Neuromuscular Agents / therapeutic use*
  • Orthotic Devices
  • Severity of Illness Index

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A